Utilisation of remote capillary blood testing in an outpatient clinic setting to improve shared decision making and patient and clinician experience: a validation and pilot study

Lisa Nwankwo, Katie McLaren, Jackie Donovan, Zhifang Ni, Alberto Vidal-Diaz, Michael Loebinger, Alice Morrissey, Adam Igra, Anand Shah

ABSTRACT

Background In a tertiary respiratory centre, large cohorts of patients are managed in an outpatient setting and require blood tests to monitor disease activity and organ toxicity. This requires either visits to tertiary centres for phlebotomy and physician review or utilisation of primary care services.

Objectives This study aims to validate remote capillary blood testing in an outpatient setting and analyse impact on clinical pathways.

Methods A single-centre prospective cross-sectional validation and parallel observational study was performed. Remote finger prick capillary blood testing was validated compared with local standard venesection using comparative statistical analysis: paired t-test, correlation and Bland-Altman. Capillary was considered interchangeable with venous samples if all three criteria were met: non-significant paired t-test (ie, p>0.05), Pearson’s correlation coefficient (r)>0.8% and 95% of tests within 10% difference through Bland-Altman (limits of agreement). In parallel, current clinical pathways including phlebotomy practice were analysed over 4 weeks to review test predictability. A subsequent pilot cohort study analysed potential impact of remote capillary blood sampling on shared decision making. A final implementation phase ensued to embed the service into clinical pathways within the institution.

Results 117 paired capillary and venous blood samples were prospectively analysed. Interchangeability with venous blood was seen with glycated haemoglobin (%), total protein and C reactive protein. Further tests, although not interchangeable, are likely useful to enable longitudinal remote monitoring (eg, liver function and total IgE). 65% of outpatient clinic blood tests were predictable with 16% of patients requiring further follow-up. Patient and clinician-reported improvement in shared decision making given contemporaneous blood test results was observed.

Conclusions Remote capillary blood sampling can be used accurately for specific tests to monitor chronic disease, and when incorporated into an outpatient clinical pathway can improve shared decision making and patient experience. Further research is required to determine health economic impact and applicability within telemedicine-based outpatient care.

INTRODUCTION

Given the current COVID-19 pandemic situation, there has been a drive to enable remote consultation including virtual internet-based telecommunication and remote monitoring tools. Tertiary respiratory centres manage large cohorts of highly COVID-19 susceptible individuals from across the whole of the country. With centrally commissioned care and prescriptions of disease-modifying therapy for patients with cystic fibrosis (CF), severe asthma or interstitial lung disease, patients often require outpatient monitoring of inflammatory or biochemical markers to determine response/toxicity, alongside therapeutic drug monitoring for antimicrobials. Even prior to the current pandemic, as prognosis has improved, these individuals are often fully independent and lead busy lives in full-time employment making regular hospital-based appointments difficult with added socioeconomic cost.

At present, however, there are no suitable easily accessible local facilities to enable remote blood monitoring for National Health Service (NHS) providers, and patients often rely on an increasingly stretched primary care resource for routine phlebotomy and monitoring, with resultant adverse socioeconomic impact. In the current COVID-19 pandemic, this is, however, problematic for individuals with high-risk diseases that require shielding. Even prior to the current scenario, primary care physicians are often uncomfortable monitoring blood tests for patients using specialist drugs and patients often feel helpless in establishing who can and should take
responsibility for monitoring. This increases failure demand\(^3\) (avoidable rework) where patients and/or primary care providers contact tertiary care providers for additional demands adding further strain on NHS resources and delay. In advanced disease, patients with chronic respiratory disease are also often limited by breathlessness and rely on relatives, friends and the NHS transport system to assist them with transportation, particularly when requiring supplemental oxygen. As chronic disease is associated with progressive social isolation, such support networks are often lacking, and likely not available with current shielding guidelines.\(^4\)–\(^8\) It is, therefore, a priority to enable practical blood monitoring solutions which are not compromised by COVID-19 shielding requirements, social isolation or lack of suitable local facilities.

Within face-to-face interactions or teleconference consultations, remote capillary blood testing (CBT) could provide contemporaneous clinical information to aid shared decision making between the patient and healthcare professional and enable efficient clinical review alongside prescription modification. Greater patient involvement has been shown to improve health outcomes and treatment adherence alongside reducing long-term healthcare cost.\(^9\) Thus, the ability to monitor remotely through CBT has the potential to streamline outpatient care, ensure better patient care, improve transparency and reduce health economic burden for patients, primary and tertiary care providers.

In this multiphase prospective cross-sectional single-centre pilot study, we aim to (1) Evaluate accuracy and usability of remote CBT in adults with chronic respiratory disease when compared with standard venesection; (2) Analyse the impact on clinical pathways in the outpatient tertiary respiratory setting to reduce failure demand and improve shared decision making and (3) Embedding into clinical pathway.

**METHODS**

This was a pilot study aimed at improving shared decision making by facilitating contemporaneous results at the time of outpatient clinic attendance. We adopted applicable elements of the extension of Consolidated Standards of Reporting Trials 2010 checklist for pilot trials\(^10\) for the implementation phase of this study.

**Setting**

The setting was a large tertiary referral respiratory centre in London.

**Study design**

A parallel phase prospective cross-sectional and observational study was designed (phase 1 and 2), followed by an implementation phase (phase 3) comprising of three iterative Plan-Do-Study-Act (PDSA) cycles:

1. Cross-sectional validation study of finger-prick remote CBT compared with gold standard (venous phlebotomy in outpatient setting).

2. Analysis of potential clinical pathway impact in outpatient tertiary respiratory care of remote CBT to reduce failure demand and improve shared decision making.

3. Implementation within institution embedding into clinical pathway and analysis of impact.

**Patients and study period**

Study subjects were recruited from within the hospital between January 2018 and October 2019. A total of 124 patients were recruited during the study period (table 1). We identified specific patients predicted to require blood tests during their routine clinic appointments. Inclusion criteria were as follows: patients \(>16\) years of age with chronic lung disease treated at the tertiary respiratory centre, and ability to provide informed consent. Exclusion criteria were: inability to provide informed consent, adults with needle phobia, currently on therapeutic dose anticoagulation or direct acting oral anticoagulants, and abnormal clotting profile or thrombocytopenia (platelet count \(<100\times10^9/L\)).

**Intervention**

The study consisted of three phases:

**Phase 1**

Once recruited, study participants had CBT performed using a blood sampling kit (Thriva) with CE marked finger-prick (capillary) sampling components by a clinical research co-ordinator and simultaneously by venesection. To imitate remote testing, capillary samples were posted (using standard first-class postage and custom UN3373 compliant transport packaging). Outpatient phlebotomy samples were sent to the laboratory as per standard clinical
blood results on shared decision making and personal experience in the outpatient setting.

Phase 3
The outpatient capillary testing service was implemented within the trust. Online supplemental figure S2 shows the iterative cycles involved. The service developed involved the process of ordering the test, the posting of the test kit from the centralised team to the patient, processing of the blood on patient return, and release of the blood test result onto the hospital’s electronic system and electronic medical records. A fully electronic requesting process was built through our order comms system so that clinicians could make the requests using a familiar system, with notification sent to a centralised team of the phlebotomy department on return of the kit by the patient.

For phase 3 deployment, a repurposed CBT kit was developed ‘in-house’ to maximise adaptability for patients, and conservation of costs, through internal sourcing and an iterative process to determine suitability to perform the home-based blood tests.

Establishing the correct packaging and postage was essential to make sure the tests were compliant. Refining the consumables meant we could improve efficiency of the service and reduce waste by using smaller envelopes and reducing postage costs. First class stamps were used to minimise time in transit, and through the patient information, the patient was advised to avoid posting during the weekend.

Patient information was iterated, taking onboard feedback from patients. We started with patient information leaflets as the minimum viable product and then developed a video recognising that capillary testing can be challenging for some patients (https://www.rbht.nhs.uk/our-services/clinical_support/home-testing). This service was advertised on the hospital’s intranet page, along with electronic mail communication to all clinical staff in the institution. A website page was also developed for patient information.

Feedback was sought from patients who had utilised the service. Some of the feedback was communicated via email directly to the hospital, and the remainder was received via an electronic System Usability Scale (SUS) questionnaire.

**Statistical analysis**
Results were presented as mean±SD, and median for numerical tests. Tests for normality were applied to the pairs of variables, and non-parametric statistics were applied to those with non-Gaussian distribution. To determine agreement between the blood collection methods a combination of three tests were performed: two-tailed paired t-test, correlation analysis (strength of association) and Bland-Altman analyses (measurement of agreement).

For the paired t-test, values of p<0.05 were deemed statistically significant meaning...
they show there was a difference between the two measurements.

Bland-Altman analysis measures the degree of agreement between two methods but does not say if these differences are acceptable or not. We have thus set clinically acceptable limits as 10% difference between the two measurement, with a priori requirement of 95% of results having to be within 10% difference.

An algorithm was developed to determine the clinical usability and interchangeability of the two methods of blood sampling (capillary and venous) (figure 1), with one point scored for each statistical test. We considered a non-significant paired t-test analysis (ie, p>0.05), Pearson’s correlation coefficient (r) greater than 0.8% and 95% of measurements within 10% difference between capillary and venous test results on Bland-Altman analysis to indicate interchangeability between the two methods.

To determine whether postal transit time or capillary sample haemolysis index value had an impact in causing significant differences between capillary and venous sample readings, a coefficient of variation (CV) analysis, expressed as a %, was applied to some tests that had a low interchangeability score of 1 (see figure 1 and table 2 for interchangeability point scoring explained). The CV is a measure of the dispersion or spread of data points around the mean and is useful in comparing the degree of variation from one data series to another; in this case capillary and venous readings.

To evaluate patient and clinician experience and their likelihood to promote the use of capillary blood sampling, the NPS was applied. The NPS presents a result from −100 (all end-users are detractors) to +100 (all end-users are promoters) by subtracting the percentage of detractors from the percentage of promoters. Users are asked a single question and rate on an 11 point scale from 10 (extremely likely) to 0 (not at all likely). Results of NPS can be benchmarked against scores obtained about other products from different domains.

Postimplementation of home-based capillary testing into a clinical pathway, to evaluate patient experience, usability and learnability of the service, an SUS questionnaire was given to patient users of the service. It comprises of a 10 scale questionnaire, with four negative questions (eg, ‘I think that I would need the support of a technical person to be able to use this system’) and six positive (eg, ‘I found the various functions in this process were well integrated’). Users rate on a five-point Likert scale with SUS scores ranging from 0 to 100, as percentiles, with a score above 60 representing the 60th percentile.

Patient and public involvement

Patients and/or the public were not involved in the design of our research. However, patients were involved in the cocation of the patient video and patient information. The novel outpatient capillary service was presented at a patient member’s event (April 2021) with positive reception from patients.

RESULTS

Phase 1: validation study

One hundred and seventeen of 124 patients recruited completed the study by providing both capillary and venous blood samples. Variation in number of paired samples was dependent on both numbers recruited for each group, or either haemolysis of the blood samples or insufficient blood in the sample to allow for analysis of all the tests within the subgroups. During the study, it was determined that due to the volume of capillary tube, 3–4 tests could be performed from one tube, and where more tests were needed, additional tube (s) will be required.

Statistical analysis revealed that HbA1C (%), CRP and total protein met a priori criteria to demonstrate interchangeability to venous blood (table 1). HbA1C (International Federation of Clinical Chemistry and Laboratory Medicine (IFCC)) had 95% CIs just outside of 10% difference but a small bias (average difference between results) (~1%) suggesting high clinical usability. A number of tests such as alanine transferase (ALT), alkaline phosphatase (ALP), vitamin D, total IgE had non-significant difference by paired t-test, with strong correlation (r or rs>0.8) but 95% CIs greater than 10% by Bland-Altman analysis (table 1, and figure 2). ALT and ALP had small bias however (2.75% and 1.61%, respectively) suggesting good clinical usability, with vitamin D and total IgE showing a larger bias (7.3% and 34%, respectively). Bland-Altman analysis is also shown in online supplemental table S1 and online supplemental figure S4. Paired t comparison is shown in figure 3 and online supplemental figure S3, and correlation analysis is shown in figure 4 and online supplemental figure S5.

Potassium showed significant difference in paired t-test, weak correlation and wide limits of agreement in Bland-Altman analysis suggesting capillary blood sampling is unreliable compared with venous blood. A number of other tests showed strong correlation, but significantly differed in paired t-test with wide limits of agreement in Bland-Altman analysis (eg, bilirubin, white cell count (WCC), platelets, urea, creatinine). This suggests although significantly different compared with venous blood, capillary testing, given the strong correlation, may potentially have a role in longitudinal monitoring but further analysis is necessary to understand clinical usability and longitudinal variability.

The majority of capillary samples went through the Royal Mail postal system via first class post and were received into the hospital laboratories for analysis within 1-day (see online supplemental table S2); transit duration (days) of capillary samples) with a median transit time of 1 day). Samples with longer transit time did not show a greater CV than shorter intransit times, but it was apparent in this study that samples that were in transit for longer than 4 days had a greater propensity to clot...
Table 2: Analysis of remote capillary versus venous phlebotomy in study subjects

<table>
<thead>
<tr>
<th>Test</th>
<th>No of paired samples</th>
<th>Mean of difference</th>
<th>SD</th>
<th>SEM</th>
<th>95% CI</th>
<th>Two-tailed p value</th>
<th>r (or r_s)</th>
<th>SD of bias (%)</th>
<th>95% limits of agreement (%)</th>
<th>Reference range of test</th>
<th>Interchangeably in clinical setting based Paired t-test p&gt;0.05</th>
<th>Interchangeably in clinical setting based on r&gt;0.8</th>
<th>Interchangeably in clinical setting based on small Bias OR max 10% difference between tests</th>
<th>Point scoring for clinical acceptability</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hb</td>
<td>30</td>
<td>−0.20</td>
<td>11.49</td>
<td>2.10</td>
<td>−4.49 to 4.09</td>
<td>0.9247</td>
<td>0.73</td>
<td>0.50 to 0.86</td>
<td>0.12 to 8.15</td>
<td>−15.9 −16.1</td>
<td>115–151 g/L</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>WCC</td>
<td>29</td>
<td>−0.69</td>
<td>1.16</td>
<td>0.22</td>
<td>−1.14 to −0.25</td>
<td>0.0033</td>
<td>0.92</td>
<td>0.83 to 0.96</td>
<td>7.88 to 12.99</td>
<td>−17.59 −22.34</td>
<td>5.1–11.4×10^{12}L</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Platelets</td>
<td>30</td>
<td>38.67</td>
<td>39.80</td>
<td>7.27</td>
<td>23.80 to 53.53</td>
<td>&lt;0.0001</td>
<td>0.93</td>
<td>0.86 to 0.97</td>
<td>−15.79 to 16.96</td>
<td>49.03 −17.44</td>
<td>147–397×10^{12}L</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>HbA1c (%)</td>
<td>31</td>
<td>−0.05</td>
<td>0.20</td>
<td>0.03</td>
<td>−0.12 to 0.026</td>
<td>0.2024</td>
<td>0.98</td>
<td>0.97 to 0.99</td>
<td>−0.80 to 3.43</td>
<td>−9.46 −11.88</td>
<td>20–42 mmol/mol</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>HbA1c (IFCC)</td>
<td>32</td>
<td>−0.47</td>
<td>2.05</td>
<td>0.36</td>
<td>−1.20 to 0.27</td>
<td>0.2024</td>
<td>0.99</td>
<td>0.97 to 0.99</td>
<td>1.21 to 5.44</td>
<td>−9.46 −11.88</td>
<td>133–146 mmol/L</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>Sodium</td>
<td>36</td>
<td>−2.22</td>
<td>2.57</td>
<td>0.43</td>
<td>−3.09 to −1.35</td>
<td>&lt;0.0001</td>
<td>0.80</td>
<td>0.64 to 0.90</td>
<td>1.57 to 1.81</td>
<td>−1.98 −5.13</td>
<td>0.93 to 0.99</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>Potassium</td>
<td>18‡</td>
<td>−1.40</td>
<td>0.94</td>
<td>0.22</td>
<td>−2.92 to −0.98</td>
<td>&lt;0.0001</td>
<td>0.75</td>
<td>0.44 to 0.90</td>
<td>27.77 to 14.19</td>
<td>−0.05 −55.48</td>
<td>5–3.5 mmol/L</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Urea</td>
<td>36</td>
<td>−0.77</td>
<td>0.55</td>
<td>0.09</td>
<td>−0.96 to 0.58</td>
<td>&lt;0.0001</td>
<td>0.96</td>
<td>0.93 to 0.98</td>
<td>14.46 to 10.15</td>
<td>−0.53 −34.35</td>
<td>2.5–7.8 mmol/L</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>Creatinine</td>
<td>36</td>
<td>−9.14</td>
<td>14.38</td>
<td>2.40</td>
<td>−14.00 to 4.27</td>
<td>0.0005</td>
<td>0.83</td>
<td>0.69 to 0.91</td>
<td>11.63 to 17.89</td>
<td>−23.43 −46.70</td>
<td>60–120 umol/L</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Bilirubin</td>
<td>59</td>
<td>−0.41</td>
<td>0.85</td>
<td>0.11</td>
<td>−0.63 to 0.18</td>
<td>0.0005</td>
<td>0.98</td>
<td>0.97 to 0.99</td>
<td>5.88 to 10.38</td>
<td>−14.47 −26.23</td>
<td>0–20 umol/L</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>ALP</td>
<td>59</td>
<td>4.10</td>
<td>55.92</td>
<td>7.28</td>
<td>−10.47 to 18.68</td>
<td>0.2561</td>
<td>0.89</td>
<td>0.82 to 0.93</td>
<td>1.61 to 19.90</td>
<td>−37.39 −40.61</td>
<td>30–130 IU/L</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>ALT</td>
<td>59</td>
<td>−0.70</td>
<td>3.66</td>
<td>0.48</td>
<td>−1.85 to 0.26</td>
<td>0.7827</td>
<td>0.98</td>
<td>0.97 to 0.99</td>
<td>2.75 to 13.20</td>
<td>−23.12 −23.62</td>
<td>8–40 IU/L</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Total protein</td>
<td>58</td>
<td>0.26</td>
<td>2.92</td>
<td>0.36</td>
<td>−0.51 to 0.26</td>
<td>0.5032</td>
<td>0.86</td>
<td>0.78 to 0.92</td>
<td>−0.37 to 3.92</td>
<td>−8.07 −7.32</td>
<td>60–80 g/L</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Total IgE</td>
<td>35</td>
<td>12.23</td>
<td>34.98</td>
<td>5.91</td>
<td>0.21 to 24.24</td>
<td>0.7104</td>
<td>0.99</td>
<td>0.99 to 1.00</td>
<td>−34.87 to 69.23</td>
<td>−107.6 −100.80</td>
<td>3–150 IU/mol</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Vit D</td>
<td>26‡</td>
<td>−0.89</td>
<td>12.72</td>
<td>2.50</td>
<td>−6.02 to 4.25</td>
<td>0.7258</td>
<td>0.90</td>
<td>0.78 to 0.95</td>
<td>−7.26 to 53.68</td>
<td>−112.5 97.96</td>
<td>50–75 mmol/L – adequate &gt;75 mmol/L – optimal</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>CRP</td>
<td>37</td>
<td>1.00</td>
<td>4.89</td>
<td>0.80</td>
<td>−0.63 to 2.63</td>
<td>0.2213</td>
<td>0.99</td>
<td>0.99 to 1.00</td>
<td>−0.41 to 4.30</td>
<td>−8.83 −8.00</td>
<td>&lt;100 mg/L</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Albumin*</td>
<td>59</td>
<td>0.00†</td>
<td>0.470</td>
<td>0.75</td>
<td>−0.61 to 0.85</td>
<td>0.0470</td>
<td>0.75</td>
<td>−0.61 to 0.85</td>
<td>−0.22 to 6.15</td>
<td>−12.27 −11.84</td>
<td>35–50 g/L</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
</tr>
</tbody>
</table>

Values in bold symbolise significant difference between the tests by p<0.05, poor correlation r or r_s<0.8, or wide limits of agreement.

Point scoring of clinical acceptability—refer to figure 1 for algorithm for determination of clinical acceptability of capillary test.

Mean, SD, SEM, CI; r, r_s, % bias, % limits of agreement to two decimal places.

Bias is the average of the differences between the two methods of blood sampling, expressed as a percentage %.

HbA1c here expressed as a percentage (%) and as a value in mmol/mol (IFCC unit).

*Non-parametric statistics applied for non-Gaussian distribution: Wilcoxon matched pairs signed rank test, non-parametric Spearman correlation r_s.

†Result represents median of difference and not mean.

‡Only 50% of potassium capillary samples were analysed due to haemolysis, and 72% of vitamin D capillary samples were analysed with the rest not processed due to insufficient blood in the capillary sample to process.

ALP: alkaline phosphatase; ALT: alanine transaminase; CI: confidence interval; CRP: C reactive protein; Hb: haemoglobin; HbA1c: glycated haemoglobin; IgE: Immunoglobulin type E; r: Pearson’s correlation coefficient; r_s: Spearman’s Rank correlation coefficient; SD: Standard deviation; SEM, SE of the mean of the differences; WCC, white cell count.
or haemolyze (see online supplemental table S2), which could render the test invalid for analysis. CV, however, was not greater with haemolysis index values of greater than zero (online supplemental table S4). From the data, there was no discernible influence of time of year on the haemolysis index value. The median and mode haemolysis index value was zero (ie, normal) for group 1 samples, and was unavailable for group 2 samples (online supplemental table S3). Potassium was the only test that showed haemolysis of large numbers of capillary sample in 18/36 tests, and thus only 50% of potassium capillary samples were analysed due to haemolysis.

**Phase 2: clinical pathway mapping**

Parallel to the validation study, a 4-week prospective analysis of blood testing in outpatient clinics was undertaken with a total of 15 clinics and 181 patients. Sixty-three patients underwent blood testing (35%). Of the patients who required blood testing in clinic, six patients were unable to have blood tests when required; four due to
unavailability of phlebotomy services and two because tests were time specific. Sixteen per cent (n=10) of patients had to be contacted after clinic by the clinical team following blood results to action a change in clinical plan such as recommendation of follow-up general practitioner visit/change in prescription, etc.

Indication and predictability were assessed for each patient based on pre-existing medical history. 65% (n=41) of blood tests were predictable prior to clinic appointment. Of predictable blood tests, 78% (n=32) (and so 51% of all blood tests) were tests that were deemed interchangeable or clinically acceptable using capillary blood sampling based on the validation study.

Specific groups of patients were identified who were predicted to require blood tests during their routine clinic appointments and a novel clinical pathway was designed (see online supplemental figure S1). Once received, the patient performed the test at home. They then return-posted the CBT sample to the hospital where the hospital laboratory processed the sample. This ensured results were available in advance of clinic appointment. Over a 2-week period and six outpatient clinics, 26 patients were contacted by phone to be involved in the remote capillary blood sampling pilot. Of those, seven patients were unable to be contacted by phone and five declined. Fourteen patients agreed to take part in the pilot and were sent the Thriva finger-prick capillary blood sampling device in the post. Of these, eight patients had blood tests available to them when they attended clinic. As part of the ‘Study’ phase of the PDSA cycle (see online supplemental figure S2), we analysed system failures and barriers to use. There was a range of reasons for the other patients’ results not being available in clinic. One patient put the label on the packaging and not directly on the blood bottle, two patients found the process difficult to collect the capillary blood, one patient received the sampling kit too late to send in time for the clinic appointment and one patient sent the capillary blood sample but it had not arrived in time for their clinic appointment.

The NPS score showed very good usability of the capillary test (figure 5). Feedback from study participants were obtained and 5 patients were ‘very satisfied’ with the home blood testing kits, 2 were ‘quite satisfied’ and 1 was ‘neither satisfied nor dissatisfied’. All eight patients either ‘very much agreed’ or ‘agreed’ with the following statements:

1. Did you feel the process resulted in better decision making and planning?
2. Did you feel more involved in your care?
3. Did doing the tests at home save time in clinic?

For the eight patients where contemporaneous blood results were available to the treating clinician and following completion of the clinic visit, they provided feedback from a clinician perspective. In all eight clinical interactions, it was either ‘very much agreed’ or ‘agreed’ on the following questions: Do you feel that having the blood results available helped shared decision making and care planning? Did the process change your clinical interaction with the patient? In all but one clinical interaction, it was felt that the process helped save time in clinic.

Phase 3: implementation into outpatient clinical pathways within the institution

After roll-out of the outpatient capillary testing service within the hospital for tests that had an interchangeability score 1–3, 140 requests were made by clinicians for CBT for routine monitoring of their patients between February 2021 and May 2021.

Specialties using the service were diverse including multiple specialist respiratory and cardiology services. Of eight completely independent patient respondents than those in phase 2, who returned a completed SUS questionnaire, a score of 61 was achieved. This SUS score demonstrates above average usability of the capillary test and the outpatient capillary service in practice. For the positive questions a score of 68.5 was achieved. For the negative questions, user feedback was 48.7.
Objective feedback via electronic email and the comments section of the SUS questionnaire are summarised in online supplemental table S5.

**DISCUSSION**

The use of remote CBT to streamline chronic disease outpatient care has not been previously evaluated. In this prospective cross-sectional observational multiple-phased study, we evaluate the accuracy and usability of remote capillary blood sampling and determine the potential impact in outpatient clinical pathway mapping and potential usability to facilitate virtual cohort monitoring as required within the current COVID-19 pandemic and afterwards.

The validation study revealed interchangeability between venous and CBT in a number of blood tests.
Figure 5 Summarises the usability results from the net promoter scores-patient experience. Zero indicates the most negative experience, and 10 indicates the most positive experience.

including HbA1c, total protein and CRP testing. Further capillary tests such as ALT, ALP, total IgE, and vit D (vitamin) appear to have a place for use in clinical practice for remote monitoring given strong correlation, however, the higher levels of variation with Total IgE and vitamin D in particular suggests further confirmatory analysis will be required. Importantly, this study confirms that capillary results for certain tests such as potassium appear unreliable and should not be used within clinical practice, as delays in analysis affects the final reading.21–24 Interchangeability score was low for creatinine testing, but the Jaffe method used for creatinine analysis at our labs have some influence in this,25 as it is more susceptible to interferences compared with enzymatic assays.26 Capillary and venous creatinine blood comparisons may produce differing results where this study is repeated with creatine sampling done in labs with more specific enzymatic assays.

A number of tests (eg, bilirubin, WCC, platelets, urea, creatinine) appear significantly different from venous blood but highly correlated suggesting a possible role in intrapatient longitudinal monitoring in the outpatient setting for patients with long term clinical diseases. Differences in capillary and venous Haemoglobin counts is long established but the mechanism for this is unknown.23 WCC and platelets have been similarly affected, with some studies describing non-significant differences28 and some recognising that there are differences29 with greater precision achievable with venous blood.27 As in our study, good correlation has been observed in the literature with capillary and venous comparisons of WCC although in different patient populations such as oncology28 or healthy athletes.30 Though it cannot be said that they are interchangeable, clinical utility can be considered for a number of tests (eg, sodium and bilirubin) as good correlation and low bias was demonstrated. Similarly, albumin, and haemoglobin had small bias and Bland-Altman in the former was close to the 10% difference. Results should, however, be interpreted with caution and further analysis with larger numbers is required to understand its clinical utility where interchangeability is desired.

Outliers exist in the data set that could possibly skew the data and potentially skew the agreements and associations between venous and capillary samples. This is evident in results for haemoglobin and ALP, for example (see figure 2). These were not excluded from the analysis because at this stage the cause(s) of the outlier(s) are unknown, and could be technical or human factor related. Further work on human factor and process analysis will be required to understand cause and potential impact. This will be key to enable adoption within novel clinical pathways, given the absence of a contemporaneous venous result for comparison.

As a pilot study, the results are limited by size and its cross-sectional nature. In addition, any choice of statistical analysis of agreement has limitations. Although using ‘a priori’ percentage difference limits within Bland-Altman analysis can be useful as a measure of agreement for tests where the normal range is wide (eg, total IgE, which can range from single figures to thousands), it can be problematic in dealing with clinically insignificant change within normal range although with a high ‘percentage’ change. In translating to a clinical setting, larger multicentre studies will be required to analyse ‘clinically meaningful change’ and to determine use within screening protocols (eg, vitamin D, haemoglobin), analysing sensitivity and specificity. Within chronic disease, as the majority of testing relates to longitudinal monitoring, further longitudinal analysis is required, but the high correlation coefficients seen in a number of tests (eg, liver function, CRP, total IgE, HbA1c) suggest capillary testing may be an extremely useful practical tool for clinicians. These tests are highly clinically relevant and have a range of uses, such as disease monitoring and drug toxicity monitoring. Within chronic respiratory disease care, given a large proportion of ongoing monitoring relates to allergy, infection and hepatotoxicity this is particularly useful. The ability to accurately remotely monitor HbA1c is potentially also helpful across chronic disease, but also in tertiary respiratory care where ~50% of adults with CF have diabetes.31

Our study shows good usability of remote capillary testing. These results are promising for real life implications as the capillary samples were all posted using the UK Royal Mail postal service to reflect a real clinical pathway. Results showed the tests were largely stable within the postal system for up to 6 days, and could be used provided the samples have not haemolysed. Also the time of year and thus temperature had no discernible influence on haemolysis index value. The recommendation if haemolysis occurs will be to request a repeat capillary sample.

There is a recognised inefficiency in the form of failure demand in healthcare when clinical results need to be reviewed and plans amended after the time of clinical interaction. Our analysis of clinic blood testing showed that
16% of patients who underwent blood testing needed to be contacted at a later date by a healthcare professional to amend the initial clinical plan put in place at the time of the clinic appointment. This is time-consuming and costly for both healthcare professionals and patients. Furthermore, we revealed that over half of the blood tests performed in our chronic respiratory disease clinics could potentially both be predicted and provided by remote CBT. This is particularly pertinent in the current COVID-19 pandemic, where a large percentage of testing could be predicted and reliably achieved remotely to facilitate virtual consultation in a shielded population.

To show proof of principle, we designed a small pilot study to target inefficiency and streamline blood monitoring in chronic respiratory disease care. This showed good subjective evidence that patients felt more involved in care and healthcare professionals found it saved time in clinic. Within our pilot study, we rolled out an early model to learn from the successes and barriers through a PDSA cycle of learning (online supplemental figure S2) and map out the follow on actions to be undertaken (‘Act’ phase).

During real-time use of the capillary testing in routine clinical practice, feedback from patients highlighted the need for more support with educational material provided, some experienced pain with the process, or expressed some concern with the new service. The above average SUS score showed that there is usability for the service and that with continued use, increased confidence with performing the home testing is achievable.

Further evaluation is required to determine impact on clinical pathways within a complete virtual remote care platform, alongside health economic modelling to assess impact on time, cost and clinical decision-making outcomes.

Though the initial focus of this work was within a face-to-face outpatient clinic setting, we recognise the implications in the current COVID-19 pandemic to enable rapid expansion of remote chronic disease care for highly susceptible cohorts. Remote CBT monitoring is a very attractive solution to maintaining continuity of healthcare provision while improving patient experience by reducing socioeconomic impact, mitigating infection risk in highly vulnerable individuals and enabling contemporaneous clinical information at time of review. We have developed a proposed novel clinical pathway (see online supplemental figure S1) to enable use within either an outpatient, ambulatory or completely virtual telemedicine scenario for further larger-scale validation. Using quality improvement methodology we rapidly developed a working service within weeks, but we were able to (over months) refine it, working collaboratively with pathology, senior clinicians, phlebotomy, postrooms and management teams. We iteratively learnt, acted and improved by ‘doing’, rather than prolonged planning. Through this work, we have now developed a service, we believe, is the first of its kind in the NHS.

In summary, in this pilot study, we analyse the accuracy of remote CBT compared with standard venesection, show usability and demonstrate integration of this novel clinical care pathway into routine clinical practice to facilitate remote chronic disease monitoring with high applicability to the current COVID-19 pandemic and beyond.

Author affiliations
1Pharmacy, Royal Brompton and Harefield NHS Foundation Trust, London, UK
2Department of Respiratory Medicine, Royal Brompton and Harefield NHS Foundation Trust, London, UK
3Department of Pathology, Royal Brompton and Harefield NHS Foundation Trust, London, UK
4Faculty of Medicine, Department of Surgery and Cancer, Imperial College London, London, UK
5National Heart and Lung Institute, London, UK
6Royal Brompton and Harefield NHS Foundation Trust, London, UK
7MRC Centre of Global Infectious Disease Analysis, Department of Infectious Disease Epidemiology, School of Public Health, Imperial College, London, UK

Twitter Lisa Nwankwo @abxLisa

Contributors AS conceived the idea, edited and reviewed the manuscript, LN wrote the manuscript, performed the statistical analysis and edited the manuscript, KM coordinated the study and contributed to the writing and review of the manuscript, ZN and AV-D provided advice and guidance on the statistical analysis, JD provided advise on laboratory procedures, and reviewed the manuscript, ML reviewed the manuscript, AM and AI provided data of embedding of project into a clinical pathway, and contributed to the writing of the manuscript.

Funding This work was funded by NHS England Darzi fellowship in Clinical Leadership (KM) and Thriva.co. The authors LN, JD, ZN, AV-D, ML, AM, AI and AS have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Competing interests None declared.

Patient consent for publication Not required.

Ethics approval Study materials and protocols were approved by the North West-Haydock Research Ethics Committee (REC reference: 18/NW/0491) with informed written consent obtained at participant’s clinic visit or inpatient stay.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available on reasonable request. All data relevant to the study are included in the article or uploaded as online supplemental information.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iD
Lisa Nwankwo http://orcid.org/0000-0001-9146-2873

REFERENCES


Nesta. The business case for people powered health, 2013.


Supplementary Tables and Figures legend

**Figure S1:** Novel clinical pathway

**Figure S2:** PDSA cycle-Plan, Do, Study, Act

**Figure S3:** Paired T comparison for capillary and venous samples

**Figure S4:** Bland-Altman comparison for capillary and venous samples

**Figure S5:** Correlation of measurements (xy analysis)

**Table S1:** Analysis of remote capillary versus venous phlebotomy in study subjects - Absolute values of Bland-Altman

**Table S2:** Transit duration (days) of capillary samples

**Table S3:** Haemolysis index value of capillary samples

**Table S4:** Review of impact of transit time duration (days) or Haemolysis index value

**Table S5:** Objective patient feedback

---

**Figure S1:** Novel clinical pathway. Grey-shaded boxes indicates adjustments to future clinical pathways to improve availability of contemporaneous results.

CBT – Capillary blood test
Supplemental material

Figure S2: PDSA cycle-Plan, Do, Study, Act. The plan phase describes the problem, the Do phase is where a small change is implemented, the Study phase allows analysis of what worked, and lessons learned, and the Act phase allows consideration of next steps.

Figure S3: Paired T comparison for capillary and venous samples - additional result IgE-Immunoglobulin type E.
Figure S4: Bland-Altman comparison for capillary and venous samples -additional results
IgE-Immunoglobulin type E

Figure S5: Correlation of measurements (xy analysis) -additional results
ALP-Alkaline phosphatase
Table S1: Analysis of remote capillary versus venous phlebotomy in study subjects - Absolute values of Bland Altman

<table>
<thead>
<tr>
<th>Test</th>
<th>N° of paired samples</th>
<th>Bias</th>
<th>SD of bias</th>
<th>95% Limits of Agreement</th>
<th>Reference range of test</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>From</td>
<td>To</td>
</tr>
<tr>
<td>Hb</td>
<td>30</td>
<td>0.20</td>
<td>11.49</td>
<td>-22.32</td>
<td>22.72</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>115 - 151 g/L</td>
<td></td>
</tr>
<tr>
<td>WCC</td>
<td>29</td>
<td>0.69</td>
<td>1.16</td>
<td>-1.583</td>
<td>2.969</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>5.1 - 11.4 10/L</td>
<td></td>
</tr>
<tr>
<td>Platelets</td>
<td>30</td>
<td>-38.67</td>
<td>39.80</td>
<td>-116.7</td>
<td>39.35</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>147 - 397 10/L</td>
<td></td>
</tr>
<tr>
<td>HbA1c</td>
<td>31</td>
<td>0.05</td>
<td>0.19</td>
<td>-0.333</td>
<td>0.423</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>-146 mmol/mol</td>
<td></td>
</tr>
<tr>
<td>HbA1c (IFCC)</td>
<td>32</td>
<td>0.47</td>
<td>2.05</td>
<td>-3.544</td>
<td>4.482</td>
</tr>
<tr>
<td>Sodium</td>
<td>36</td>
<td>2.22</td>
<td>2.57</td>
<td>-2.805</td>
<td>7.249</td>
</tr>
<tr>
<td>Potassium</td>
<td>18*</td>
<td>1.45</td>
<td>0.94</td>
<td>-0.4012</td>
<td>3.301</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3.5 - 5.3mmol/L</td>
<td></td>
</tr>
<tr>
<td>Urea</td>
<td>36</td>
<td>0.77</td>
<td>0.55</td>
<td>-0.3171</td>
<td>1.856</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2.5 - 7.8 mmol/L</td>
<td></td>
</tr>
<tr>
<td>Creatinine</td>
<td>36</td>
<td>14.14</td>
<td>21.38</td>
<td>-19.04</td>
<td>37.32</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>60 - 120 umol/L</td>
<td></td>
</tr>
<tr>
<td>Bilirubin</td>
<td>59</td>
<td>0.41</td>
<td>0.85</td>
<td>-1.266</td>
<td>2.079</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0 – 20 umol/L</td>
<td></td>
</tr>
<tr>
<td>ALP</td>
<td>59</td>
<td>-4.10</td>
<td>89.90</td>
<td>-113.7</td>
<td>105.5</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>30 - 130 IU/L</td>
<td></td>
</tr>
<tr>
<td>ALT</td>
<td>59</td>
<td>0.70</td>
<td>3.66</td>
<td>-15.95</td>
<td>15.37</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>8 – 40 IU/L</td>
<td></td>
</tr>
<tr>
<td>Total protein</td>
<td>58</td>
<td>-0.26</td>
<td>2.92</td>
<td>-6.486</td>
<td>7.876</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>60 - 80 g/L</td>
<td></td>
</tr>
<tr>
<td>Albumin</td>
<td>59</td>
<td>-0.08</td>
<td>2.588</td>
<td>-5.158</td>
<td>4.988</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>35 - 50 g/L</td>
<td></td>
</tr>
<tr>
<td>Total IgE</td>
<td>35</td>
<td>-12.23</td>
<td>34.98</td>
<td>-80.79</td>
<td>56.33</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3-150 IU/mol</td>
<td></td>
</tr>
<tr>
<td>Vit D</td>
<td>26*</td>
<td>0.89</td>
<td>12.72</td>
<td>-24.05</td>
<td>25.81</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>30 - 75 mmol/l</td>
<td>adequate</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>&gt;75 mmol/l</td>
<td>optimal</td>
</tr>
<tr>
<td>CRP</td>
<td>37</td>
<td>-1.00</td>
<td>4.89</td>
<td>-10.58</td>
<td>8.58</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>&lt;100mg/L</td>
<td></td>
</tr>
</tbody>
</table>

*Only 50% of potassium capillary samples were analysed due to haemolysis, and 72% of vitamin D capillary samples were analysed with the rest not processed due to insufficient blood in the capillary sample to process Bias, SD of bias, Limits of Agreement to 2 decimal places (dp).

Key: ALP - Alkaline phosphatase, ALT - Alanine Transferase, CRP - C-Reactive protein, IgE - Immunoglobulin type E, Hb - Haemoglobin, HbA1c - glycated haemoglobin, HbA1c here expressed as a percentage (%) and as a value in mmol/mol (IFCC unit). Vit - Vitamin, SD = standard deviation. LOA = Limits of agreement; within which 95% of samples are predicted to lie.

Table S2: Transit duration (days) of capillary samples

<table>
<thead>
<tr>
<th>Group</th>
<th>Number of paired samples</th>
<th>Range (days)</th>
<th>Median (days)</th>
<th>Mode (days)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group 1</td>
<td>37</td>
<td>1-6</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Group 2</td>
<td>35</td>
<td>1-6</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Total</td>
<td>72</td>
<td>1-6</td>
<td>1</td>
<td>1</td>
</tr>
</tbody>
</table>

From Group 2, one sample that was 21 days in transit was not analysed as clotted, and one sample haemolysed after 6 days in transit.
Table S3: Haemolysis index value of capillary samples

<table>
<thead>
<tr>
<th>Group</th>
<th>Number of paired samples</th>
<th>Range</th>
<th>Median</th>
<th>Mode</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group 1</td>
<td>36*</td>
<td>0-2</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Group 2</td>
<td>n/a</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Haemolysis index value is expressed as a number between 0 and 5. A haemolysis index value of zero is normal. n/a - not available.

*Only 50% of potassium capillary samples were analysed due to haemolysis

Table S4: Review of impact of transit time duration (days) or Haemolysis index value

<table>
<thead>
<tr>
<th>Transit time</th>
<th>0-2 days</th>
<th>0-3 days</th>
<th>3 days</th>
<th>4-6 days</th>
</tr>
</thead>
<tbody>
<tr>
<td>Urea</td>
<td>37%</td>
<td>37%</td>
<td>37%</td>
<td>32%</td>
</tr>
<tr>
<td>Creatinine</td>
<td>35%</td>
<td>33%</td>
<td>16%</td>
<td>18%</td>
</tr>
<tr>
<td>Bilirubin</td>
<td>47%</td>
<td>47%</td>
<td>38%</td>
<td>35%</td>
</tr>
<tr>
<td>ALT</td>
<td>75%</td>
<td>86%</td>
<td>111%</td>
<td>10%</td>
</tr>
<tr>
<td>ALP</td>
<td>128%</td>
<td>117%</td>
<td>54%</td>
<td>30%</td>
</tr>
<tr>
<td>Albumin</td>
<td>8%</td>
<td>8%</td>
<td>7%</td>
<td>5%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Haemolysis index value</th>
<th>0</th>
<th>1</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Urea</td>
<td>40%</td>
<td>24%</td>
<td>10%</td>
</tr>
<tr>
<td>Creatinine</td>
<td>32%</td>
<td>21%</td>
<td>19%</td>
</tr>
<tr>
<td>Bilirubin</td>
<td>54%</td>
<td>33%</td>
<td>32%</td>
</tr>
<tr>
<td>ALT</td>
<td>89%</td>
<td>55%</td>
<td>15%</td>
</tr>
<tr>
<td>ALP</td>
<td>123%</td>
<td>28%</td>
<td>17%</td>
</tr>
<tr>
<td>Albumin</td>
<td>6.5%</td>
<td>8.8%</td>
<td>13%</td>
</tr>
</tbody>
</table>

This table gives the Coefficient of variation (CV), expressed as a %, of some variables from group 1 that had a score of 1 and 2 (Interchangeability score), to analyse if there is a difference in the readings between capillary and venous sampling methods, as a result of time in the postal service, or haemolysis of the capillary sample. There was no data available for haemolysis index in group 2.

Table S5: Objective patient feedback

'I used all three lancet devices as it was difficult to find the right place on the finger. It would be good to have a diagram to show the best places to use the device'.

'I would have liked confirmatory feedback that I had performed the test properly e.g. via email or test.

'When I unpacked the packaging, lancets didn’t match those in the written material or video.

'I realise the usefulness of this service especially as I live far away’

'Instructions were good’

'I had a lot of pain on my finger after the extraction’

'It would be easier to collect the sample if the blood test tube was wider’

'It was messy to do but I understand this was my first time, and that with repeated blood testing it will become easier’